SCGB2A2 and neoplasm: Due to the relatively large number of patients with breast cancer with matched tissue and tumor fraction estimates in our cohort (n = 33), we applied this analysis to breast biomarkers FABP7 and SCGB2A2, which were selected from 4 breast-specific DCBs due to their high recurrence rate among patients with breast cancer (13% and 24%, respectively) and specificity to different breast cancer subtypes.